On July 31, JOINN rose 5.95% in regular trading, trading at HKD 23.1/share, with turnover of HKD 49.71 million. The rally was driven by a broad-based rebound across the life sciences tools and services sector, with peers INSILICO up 7.42%, XTALPI up 2.79%, GENSCRIPT BIO up 2.79%, WUXI APPTEC up 2.03%, and WUXI BIO up 1.9%.

On the news front, the company recently confirmed on its investor interaction platform that domestic innovative drug financing and BD licensing transactions continue to recover, driving industry demand growth. Combined with low supply elasticity, non-human primate experimental animals are in a tight supply-demand state, with prices rising from prior levels. The stock had pulled back over 15% cumulatively in the two preceding trading sessions, releasing short-term oversold rebound momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)